Thanks to the Inflation Reduction Act, 2 big changes coming up for Medicare Part D beneficiaries. #MedTwitter
1) Starting 2024, once you pay ~$3250 out of pocket, you won’t have any more copays. The 5% copay you currently pay will go away. This is HUGE. #MedTwitter
2) Starting 2025, your annual copay max will be capped at $2000 for Medicare Part D.
Once you spend that much out of pocket, you won’t have any more copays for Part D prescription drugs.
Patients with cancer spend huge amounts in copays currently. The drug Revlimid I prescribe costs $17,000 for 21 day supply.
5% of $17,000 every month is a massive amount of money for most.
Lillypad announced that it is launching a Lantus equivalent biosimilar at 78% discount to Lantus starting April 1, 2023. And it’s also interchangeable with Lantus.
Sanofi has already a Lantus authorized generic at 70% discount to Lantus launched last year. Let the price drops due to competition begin! It’s good for patients.
Insulin manufacturers voluntarily slashing list prices of insulin is monumental— a result of advocacy by patients, advocates like @NSmithholt12 & leaders like @SenSanders
@novonordiskus will cut list price of NovoLog by 75% and Levemir by 65%. Starts January 2024.
Next up, I hope @SanofiUS will follow suit. They make the best seller Lantus.
We also need policy changes at federal level to make this relief enduring and to make sure manufacturers don’t hike prices again. To help all other prescription drugs.